Literature DB >> 24825058

22 again: IL-22 as a risk gene and important mediator in psoriasis.

Andrew Johnston1, Johann E Gudjonsson2.   

Abstract

IL-22 targets our external epithelial barriers, bolstering our defenses, and has long been implicated in the pathogenesis of psoriasis. Nikamo and colleagues (2014) identify a haplotype in the IL22 promoter with a strong association to juvenile-onset psoriasis and demonstrate that this risk variant is associated with increased IL-22 production by T cells. We explore the implications of this work.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24825058     DOI: 10.1038/jid.2014.81

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy.

Authors:  Yuan-Hsin Lo; Kan Torii; Chiyo Saito; Takuya Furuhashi; Akira Maeda; Akimichi Morita
Journal:  J Dermatol Sci       Date:  2010-04-03       Impact factor: 4.563

Review 2.  Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease.

Authors:  Wenjun Ouyang
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-23       Impact factor: 7.638

3.  The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis.

Authors:  Susan M Sa; Patricia A Valdez; Jianfeng Wu; Kenneth Jung; Fiona Zhong; Linda Hall; Ian Kasman; Jane Winer; Zora Modrusan; Dimitry M Danilenko; Wenjun Ouyang
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

4.  Genetic variants of the IL22 promoter associate to onset of psoriasis before puberty and increased IL-22 production in T cells.

Authors:  Pernilla Nikamo; Stanley Cheuk; Josefin Lysell; Charlotta Enerbäck; Kerstin Bergh; Ning Xu Landén; Liv Eidsmo; Mona Ståhle
Journal:  J Invest Dermatol       Date:  2013-01-03       Impact factor: 8.551

5.  Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells.

Authors:  Jean-Marie Ramirez; Nicolò C Brembilla; Olivier Sorg; Rachel Chicheportiche; Thomas Matthes; Jean-Michel Dayer; Jean-Hilaire Saurat; Eddy Roosnek; Carlo Chizzolini
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

6.  Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis.

Authors:  Ellen H van den Bogaard; Judith G M Bergboer; Mieke Vonk-Bergers; Ivonne M J J van Vlijmen-Willems; Stanleyson V Hato; Pieter G M van der Valk; Jens Michael Schröder; Irma Joosten; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

7.  The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins.

Authors:  Marc Veldhoen; Keiji Hirota; Astrid M Westendorf; Jan Buer; Laure Dumoutier; Jean-Christophe Renauld; Brigitta Stockinger
Journal:  Nature       Date:  2008-03-23       Impact factor: 49.962

Review 8.  Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals.

Authors:  Michael S Denison; Scott R Nagy
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

9.  A role for T cell-derived interleukin 22 in psoriatic skin inflammation.

Authors:  K Boniface; E Guignouard; N Pedretti; M Garcia; A Delwail; F-X Bernard; F Nau; G Guillet; G Dagregorio; H Yssel; J-C Lecron; F Morel
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

Review 10.  Therapeutic opportunities of the IL-22-IL-22R1 system.

Authors:  Robert Sabat; Wenjun Ouyang; Kerstin Wolk
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

View more
  7 in total

1.  Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus.

Authors:  Liana C Chan; Siyang Chaili; Scott G Filler; Kevin Barr; Huiyuan Wang; Deborah Kupferwasser; John E Edwards; Yan Q Xiong; Ashraf S Ibrahim; Lloyd S Miller; Clint S Schmidt; John P Hennessey; Michael R Yeaman
Journal:  Infect Immun       Date:  2015-09-08       Impact factor: 3.441

Review 2.  Interleukin-22: immunobiology and pathology.

Authors:  Jarrod A Dudakov; Alan M Hanash; Marcel R M van den Brink
Journal:  Annu Rev Immunol       Date:  2015-02-11       Impact factor: 28.527

3.  Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model.

Authors:  R Palombo; I Savini; L Avigliano; S Madonna; A Cavani; C Albanesi; A Mauriello; G Melino; A Terrinoni
Journal:  Cell Death Dis       Date:  2016-08-18       Impact factor: 8.469

4.  Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.

Authors:  Shuna Sun; Xiaojie Zhang; Mengru Xu; Fang Zhang; Fei Tian; Jianfeng Cui; Yangyang Xia; Chenxi Liang; Shujie Zhou; Haifeng Wei; Hui Zhao; Guojing Wu; Bohan Xu; Xiaochen Liu; Guanqun Yang; Qinzhou Wang; Lei Zhang; Yaoqin Gong; Changshun Shao; Yongxin Zou
Journal:  Cell Death Dis       Date:  2019-03-20       Impact factor: 8.469

5.  Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.

Authors:  Remy A Pollock; Laila Zaman; Vinod Chandran; Dafna D Gladman
Journal:  PLoS One       Date:  2019-02-19       Impact factor: 3.240

6.  Acitretin-Conjugated Dextran Nanoparticles Ameliorate Psoriasis-like Skin Disease at Low Dosages.

Authors:  Jiajia Lan; Yuce Li; Jingjing Wen; Yu Chen; Jing Yang; Liang Zhao; Yuting Xia; Hongyao Du; Juan Tao; Yan Li; Jintao Zhu
Journal:  Front Bioeng Biotechnol       Date:  2022-01-07

7.  NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris.

Authors:  Recep Dursun; Hatice Gül Dursun; Ayşe Gül Zamani; Mahmut Selman Yıldırım; İlknur Çınar
Journal:  Biomed Res Int       Date:  2018-06-11       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.